Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1990-8-17
|
| pubmed:abstractText |
Dilevalol, 200 mg, was administered orally as seven daily doses to three groups of six participants, with differing degrees of renal impairment. Values of Cmax, Tmax, half-life or renal elimination did not significantly change with decreased renal function. Values of area under the plasma concentration-time curves and pre-dose concentrations tended to increase with renal impairment and there was a significant, if small, correlation between these and glomerular filtration rate. The practical clinical consequences of these results is that impairment is not likely to be associated with significant accumulation of dilevalol.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0950-9240
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4 Suppl 2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
59-62
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:2370645-Administration, Oral,
pubmed-meshheading:2370645-Adult,
pubmed-meshheading:2370645-Aged,
pubmed-meshheading:2370645-Female,
pubmed-meshheading:2370645-Glomerular Filtration Rate,
pubmed-meshheading:2370645-Half-Life,
pubmed-meshheading:2370645-Humans,
pubmed-meshheading:2370645-Hypertension,
pubmed-meshheading:2370645-Kidney Failure, Chronic,
pubmed-meshheading:2370645-Labetalol,
pubmed-meshheading:2370645-Male,
pubmed-meshheading:2370645-Middle Aged,
pubmed-meshheading:2370645-Reference Values
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
The pharmacokinetics of dilevalol in renal impairment.
|
| pubmed:affiliation |
Institute of Biopharmaceuticals, Athlone, Ireland.
|
| pubmed:publicationType |
Journal Article
|